Conflict of interest statement: The authors declare no conflict of interest.166. Clin Cancer Res. 2018 Jul 16. pii: clincanres.3125.2017. doi:10.1158/1078-0432.CCR-17-3125. [Epub ahead of print]Activating transcription factor 4 modulates TGFβ-induced aggressiveness in triplenegative breast cancer via SMAD2/3/4 and mTORC2 signaling.González-González A(1), Muñoz-Muela E(1), Marchal JA(2), Cara FE(1), MolinaMP(1), Cruz-Lozano M(1), Jiménez G(2), Verma A(3), Ramírez A(4), Qian W(5), Chen W(6), Kozielski AJ(6), Elemento O(3), Martin-Salvago MD(7), Luque RJ(7),Rosa-Garrido C(8), Landeira D(9), Quintana-Romero M(9), Rosato RR(4), GarcíaMA(10), Ramírez-Tortosa CL(11), Kim H(12), Rodriguez-Aguayo C(13),Lopez-Berestein G(13), Sood AK(14), Lorente JA(15), Sánchez-Rovira P(16), ChangJC(17), Granados-Principal S(18).Author information: (1)UGC Oncologia Medica, Complejo Hospitalario de Jaén.(2)Departamento de Anatomía y Embriología Humana, Facultad de Medicina,Universidad de Granada, Instituto de Biopatología y Medicina Regenerativa(IBIMER).(3)Institute for Computational Biomedicine, Weill Cornell Medical College.(4)Houston Methodist Cancer Center, Houston Methodist Hospital.(5)Cancer Center, Houston Methodist Hospital.(6)HM Cancer Center, Houston Methodist Research Institute.(7)UGC Anatomía Patológica, Complejo Hospitalario de Jaén.(8)Complejo Hospitalario de Jaén, Fundación Pública Andaluza para laInvestigación Biosanitaria de Andalucía Oriental (FIBAO).(9)Biochemistry and Molecular Biology II, University of Granada.(10)Department of Oncology, Virgen de las Nieves, University Hospital.(11)Department of Pathology, Complejo Hospitalario de Jaén.(12)Texas Tech University Health Sciences Center.(13)Center for RNA Interference and Non-Coding RNA, MD Anderson Cancer Center.(14)Department of Gynecologic Oncology and Reproductive Medicine, University ofTexas MD Anderson Cancer Center.(15)Centre for Genomics and Oncological Research, Pfizer-University ofGranada-Andalusian Government Center of Genomics and Oncology (GENyO).(16)Medical Oncology Department, Complejo Hospitalario de Jaén.(17)Radiation Oncology, Houston Methodist Research Institute.(18)UGC Oncologia Medica, Complejo Hospitalario de Jaénsergio.granados.exts@juntadeandalucia.es.PURPOSE: Based on the identified stress-independent cellular functions ofactivating transcription factor 4 (ATF4), we reported enhanced ATF4 levels inMCF10A cells treated with TGFβ1. ATF4 is overexpressed in triple negative breast cancer (TNBC) patients, but its impact on patient survival and the underlyingmechanisms remain unknown. We aimed to determine ATF4 effects on breast cancerpatient survival and TNBC aggressiveness, and the relationships between TGFβ and ATF4. Defining the signaling pathways may help us identify a cellsignaling-tailored gene signature.EXPERIMENTAL DESIGN: Patient survival data was determined by Kaplan-Meieranalysis. Relationship between TGFβ and ATF4, their effects on aggressiveness(tumor proliferation, metastasis, and stemness), and the underlying pathways wereanalyzed in three TNBC cell lines and in vivo using patient-derived xenografts(PDXs).RESULTS: ATF4 overexpression correlated with TNBC patient survival decrease and aSMAD-dependent crosstalk between ATF4 and TGFβ was identified. ATF4 expressioninhibition reduced migration, invasiveness, mammosphere-forming efficiency,proliferation, epithelial-mesenchymal transition, and antiapoptotic and stemness marker levels. In PDX models, ATF4 silencing decreased metastases, tumor growth, and relapse after chemotherapy. ATF4 was shown to be active downstream ofSMAD2/3/4 and mTORC2, regulating TGFβ/SMAD and mTOR/RAC1-RHOA pathwaysindependently of stress. We defined an eight-gene signature with prognosticpotential, altered in 45% of 2509 breast cancer patients.CONCLUSIONS: ATF4 may represent a valuable prognostic biomarker and therapeutictarget in TNBC patients, and we identified a cell-signaling pathway-based genesignature that may contribute to the development of combinatorial targetedtherapies for breast cancer.Copyright ©2018, American Association for Cancer Research.DOI: 10.1158/1078-0432.CCR-17-3125 PMID: 30012564 